arrow
郝

郝勇|Yong Hao

shanghai jiao tong university
H指数:27
被引数:2,794
浏览量:0

个人简介

任职于神经病学专业,博士生导师。主要从事神经免疫病、癫痫、脑血管病的诊治与转化研究。主持国家自然科学基金项目、上海市科委生物医药科技支撑项目等多项科研项目,在国际期刊发表多篇学术论文,涉及癫痫代谢组学、神经免疫疾病多组学分析、脑炎影像学等领域。注重多学科交叉融合,推动医工结合,致力于基础研究成果的临床转化。

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Combined Double-Filtration Plasmapheresis and Corticosteroids are Associated with Improved Outcomes in Acute Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease: An Ambispective Multicenter Cohort Study

联合双重过滤血浆置换和糖皮质激素与髓鞘少突胶质细胞糖蛋白抗体相关疾病的改善结局相关:一项双向性多中心队列研究

2026-09-240
OAAI
An Immune Model Incorporating NK Cells and IL-12 to Predict the Efficacy of the Initial Treatment Cycle of Efgartigimod in Generalized Myasthenia Gravis

整合NK细胞和白介素-12的免疫模型,用于预测艾加替吉莫德在全身性重症肌无力初始治疗周期中的疗效

2026-05-180
OAAI
Guadecitabine vs TC in relapsed/refractory AML after intensive chemotherapy: a randomized phase 3 ASTRAL-2 trial
2024-04-232
OAAI
Oral decitabine-cedazuridine versus intravenous decitabine for myelodysplastic syndromes and chronic myelomonocytic leukaemia (ASCERTAIN): a registrational, randomised, crossover, pharmacokinetics, phase 3 study
2024-01-0115
PRE
Clinical impact of the genomic landscape and leukemogenic trajectories in non-intensively treated elderly acute myeloid leukemia patients (vol 37, pg 2187, 2023)
LEUKEMIA
IF13.4
2023-10-030
OAAI
Guadecitabine vs treatment choice in newly diagnosed acute myeloid leukemia: a global phase 3 randomized study
2023-08-286
OAAI
Clinical impact of the genomic landscape and leukemogenic trajectories in non-intensively treated elderly acute myeloid leukemia patients

非强化治疗的老年急性髓系白血病患者基因组景观和白血病发生轨迹的临床影响

LEUKEMIA
IF13.4
2023-08-1712
OAAI